The DOI matches its OpenAlex record; 44 of the 44 references it cites were found in a registry or an index.
Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex)
Open accessAbstract
This paper describes the establishment of an antiestrogen-resistant MCF7 breast cancer cell subline (FASMCF) by continuous culture of the estrogen-responsive parental line in steroid-depleted, ICI 182,780 (Faslodex; 10(-7) M)-supplemented medium. After a 3-month period of growth suppression, cells began to proliferate in ICI 182,780 at rates similar to those of untreated wild-type cells. Immunocytochemistry showed these cells to have reduced estrogen receptor and an absence of progesterone receptor proteins. RT-PCR and transient transfection studies with estrogen response element-reporter constructs confirmed that ICI 182,780-suppressed estrogen response element-mediated signaling. FASMCF cells show increased dependence upon epidermal growth factor receptor (EgfR)/mitogen-activated protein kinase (MAPK)-mediated signaling. Thus, EgfR protein and messenger RNA, growth responses to transforming growth factor-alpha, and extracellular signal-regulated kinase 1/2 MAPK activation levels are all increased. Unlike wild-type cells, FASMCF cells are highly sensitive to growth inhibition by an EgfR-specific tyrosine-kinase inhibitor (TKI), ZD1839 (Iressa), and an inhibitor of the activation of MEK1 (MAPKK), PD098059. Short-term ( approximately 3 weeks) withdrawal of cells from antiestrogen had no effect on growth or phenotype, whereas longer withdrawal (>10 weeks) appeared to partially reverse the cellular phenotype with increasing estrogen receptor and decreasing EgfR levels. In subsequent studies FASMCF cells were maintained in TKI, where their growth was again suppressed and secondary TKI resistance failed to develop within the 3-month period in which initial ICI 182,780 resistance arose. Furthermore, wild-type cells similarly maintained in combination ICI 182,780 and TKI treatment conditions remained growth arrested (>6 months), with notable cell loss through both reduced rates of cellular proliferation and increased cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., & Danielsen, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7413 · Cited by 4,978
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites
Paech, K., Webb, P., Kuiper, G. G. J. M., Nilsson, S., Gustafsson, J.-Å., Kushner, P. J., & Scanlan, T. S. (1997) · Science · doi:10.1126/science.277.5331.1508 · Cited by 1,861
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., & Osborne, C. K. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01961241 · Cited by 750
Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.
Dauvois, S., Danielian, P. S., White, R., & Parker, M. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.4037 · Cited by 465
ICI 182,780 (Faslodex?): Development of a novel, ?pure? antiestrogen
Howell, A., Osborne, C. K., Morris, C., & Wakeling, A. E. (2000) · Cancer · doi:10.1002/1097-0142(20000815)89:4<817::aid-cncr14>3.0.co;2-6 · Cited by 408
Katzenellenbogen, B. S., Kendra, K. L., Norman, M. J., & Berthois, Y. (1987) · PubMed · Cited by 403
Fawell, S. E., White, R., Hoare, S., Sydenham, M., Page, M., & Parker, M. G. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6883 · Cited by 396
Variant human breast tumor estrogen receptor with constitutive transcriptional activity.
Fuqua, S. A. W., Fitzgerald, S. D., Chamness, G. C., Tandon, A. K., McDonnell, D. P., Nawaz, Z., O’Malley, B. W., & McGuire, W. L. (1991) · PubMed · Cited by 394
Wright, C., Nicholson, S., Angus, B., Sainsbury, J., Farndon, J., Cairns, J., Harris, A., & Horne, C. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.22 · Cited by 379
Kurokawa, H., Lenferink, A. E. G., Simpson, J. F., Pisacane, P. I., Sliwkowski, M. X., Forbes, J. T., & Arteaga, C. L. (2000) · PubMed · Cited by 363
Osborne, C. K., Coronado-Heinsohn, E. B., Hilsenbeck, S. G., McCue, B. L., Wakeling, A. E., McCleland, R. A., Manning, D. L., & Nicholson, R. I. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.10.746 · Cited by 361
Self-citationResponse to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
Howell, A., DeFriend, D. J., Blamey, R. W., Robertson, J. F., & Walton, P. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91156-1 · Cited by 349
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.
DeFriend, D. J., Howell, A., Nicholson, R. I., Anderson, E., Dowsett, M., Mansel, R. E., Blamey, R. W., Bundred, N. J., Robertson, J. F. R., & Saunders, C. M. (1994) · PubMed · Cited by 291
Self-citationNunez, A. M., Berry, M., Imler, J. L., & Chambon, P. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03443.x · Cited by 264
Brünner, N., Frandsen, T. L., Holst‐Hansen, C., Bei, M., Thompson, E. W., Wakeling, A. E., Lippman, M. E., & Clarke, R. C. (1993) · PubMed · Cited by 238
Smith, L. M., Wise, S. C., Hendricks, D. T., Sabichi, A. L., Bos, T., Reddy, P., Brown, P. H., & Birrer, M. J. (1999) · Oncogene · doi:10.1038/sj.onc.1202989 · Cited by 213
Brünner, N., Boysen, B., JIRUS, S., Skaar, T. C., Holst‐Hansen, C., Lippman, J., Frandsen, T. L., Spang‐Thomsen, M., Fuqua, S. A. W., & Clarke, R. C. (1997) · PubMed · Cited by 196
Nicholson, R. I., McClelland, R. A., Gee, J. M. W., Manning, D. L., Cannon, P., Robertson, J. F. R., Ellis, I. O., & Blamey, R. W. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666187 · Cited by 190
Self-citationGoulding, H., Pinder, S., Cannon, P., Pearson, D., Nicholson, R., Snead, D., Bell, J., Elston, C. W. E., Robertson, J. F., Blamey, R. W., et al. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90060-8 · Cited by 182
Self-citationAntiestrogens: Mechanisms of action and resistance in breast cancer
Katzenellenbogen, B. S., Montano, M. M., Ekena, K., Herman, M. E., & McInerney, E. M. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005835428423 · Cited by 179
Nicholson, R. I., McClelland, R. A., Finlay, P., Eaton, C. L., Gullick, W. J., Dixon, A. R., Robertson, J. F. R., Blamey, R. W., & Ellis, I. O. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80215-1 · Cited by 178
Self-citationJohnston, S. R. D., Lü, B., Scott, G. K., Kushner, P. J., Smith, I. E., Dowsett, M., & Benz, C. C. (1999) · PubMed · Cited by 172
Shim, W.-S., Conaway, M., Masamura, S., Yue, W., Wang, J.-P., Kumar, R., & Santen, R. J. (2000) · Endocrinology · doi:10.1210/endo.141.1.7270 · Cited by 169
Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines
Wakeling, A. E., Barker, A. J., Davies, D. H., Brown, D. S., Green, L. R., Cartlidge, S. A., & Woodburn, J. R. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01803785 · Cited by 166
Saati, T. A., Cohen‐Knafo, E., Caveriviere, P., Delsol, G., Clamens, S., Faye, J. C., Prats, H., Bayard, F., Coindre, J., & Wafflart, J. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550423 · Cited by 143
Mechanisms of tamoxifen resistance
Osborne, C. K., & Fuqua, S. A. W. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666205 · Cited by 120
Coutts, A. S., & Murphy, L. C. (1998) · PubMed · Cited by 110
van Agthoven, T., van Agthoven, T. L., Portengen, H., et al. (1992) · PubMed · Cited by 106
Miller, D. L., El‐Ashry, D., Cheville, A. L., Liu, Y., McLeskey, S. W., & Kern, F. G. (1994) · PubMed · Cited by 93
Dumont, J. A., Bitonti, A. J., Wallace, C. D., et al. (1996) · PubMed · Cited by 89
Human breast cancer cell lines resistant to pure anti‐estrogens are sensitive to tamoxifen treatment
Lykkesfeldt, A. E., Larsen, S. S., & Briand, P. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910610417 · Cited by 86
Daly, R. J., & Darbre, P. D. (1990) · PubMed · Cited by 80
Cho, H., Ng, P. A. B., & Katzenellenbogen, B. S. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-9-1323 · Cited by 56
Sharma, A. K., Horgan, K. J., Douglas-Jones, A. G., McClelland, R. A., Gee, J. M. W., & Nicholson, R. I. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.203 · Cited by 49
Self-citationOestrogen receptor mutants and variants in breast cancer
Dowsett, M., Daffada, A. A. I., Chan, C. M. W., & Johnston, S. R. D. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00100-7 · Cited by 49
McClelland, R. A., Manning, D. L., Gee, J. M. W., Anderson, E., Clarke, R. B., Howell, A., Dowsett, M., Robertson, J. F. R., Blamey, R. W., Wakeling, A. E., et al. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01807034 · Cited by 48
Self-citationMcClelland, R. A., Gee, J. M. W., Francis, A., Robertson, J. F. R., Blarney, R. W., Wakeling, A. E., & Nicholson, R. I. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00517-x · Cited by 48
Self-citationDeFazio, A., Chiew, Y.-E., McEvoy, M., Watts, C. K. W., & Sutherland, R. L. (1997) · PubMed · Cited by 41
Knowlden, J. M., Gee, J. M. W., Bryant, S., McClelland, R. A., Manning, D. L., Mansel, R. E., Ellis, I. O., Blamey, R. W., Robertson, J. F. R., & Nicholson, R. I. (1997) · PubMed · Cited by 30
Self-citationTransition of human breast cancer cells from an oestrogen responsive to unresponsive state
Darbre, P. D., & Daly, R. J. (1990) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(90)90416-i · Cited by 29
(1994) · Endocrine Related Cancer · doi:10.1677/erc.0.0010005 · Cited by 27
Estrogen synthesis inhibitors for breast cancer: an introductory overview
Santen, R. J. (1996) · Endocrine Related Cancer · doi:10.1677/erc.0.0030001 · Cited by 15
Cited by
Estrogen receptors: how do they signal and what are their targets
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., et al. (2007) · Physiological Reviews · doi:10.1152/physrev.00026.2006 · Cited by 1,857
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
BindingDB (2025) · PubMed · doi:10.7270/q2pc374f · Cited by 924
Mechanisms of tamoxifen resistance
Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651
Arpino, G., Wiechmann, L., Osborne, C. K., & Schiff, R. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0045 · Cited by 549
Metadata
- Authors
- McClelland, R. A., Barrow, D., Madden, T., Dutkowski, C. M., Pamment, J., Knowlden, J. M., Gee, J. M. W., & Nicholson, R. I.
- Venue
- Endocrinology
- Publisher
- Oxford University Press
- Published
- 2001-07-01
- Volume
- 142
- Issue
- 7
- Pages
- 2776-2788
- ISSN
- 0013-7227 (ISSN-L)
- OpenAlex
- W1999444744
- Cited by
- 258
- References
- 44
- FWCI
- 10.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.